Beigene Ltd ADR (ONC) Stock Price, Quote & News

Company Profile

BeOne Medicines AG, an oncology company, engages in discovering and developing various treatments for cancer patients in the United States, China, Europe, and internationally. The company's commercial stage products include BRUKINSA, a small molecule inhibitor of Bruton's Tyrosine Kinase (BTK) for the treatment of various blood cancers; TEVIMBRA, an anti-PD-1 antibody immunotherapy for the treatment of various solid tumor and blood cancers; and PARTRUVIX, a selective small molecule inhibitor of...

Industry: Biotechnology

Sector: Healthcare

Phone: 41 61 685 19 00

Website: beonemedicines.com

Address:

Aeschengraben 27, 21st Floor, Basel, Switzerland

SuperGreenToday Oct. 22 at 10:47 PM

$ONC Share Price: $313.96 Contract Selected: May 15, 2026 $310 Calls Buy Zone: $39.95 – $49.35 Target Zone: $71.51 – $87.40 Potential Upside: 69% ROI Time to Expiration: 204 Days | Updates via https://fxcapta.com/stockinfo/

0 · Reply

MoneyGroupLLC Oct. 22 at 7:25 AM

Enter: $ONC NOV 21 2025 $320 CALLS Buy in Price: $19.40 - $20.40 Take Profit: $44.81 Stop Bleeding: $17.07 ROI Potential: 131% Exit Within: 2 Weeks https://moneygroup.us/alerts

0 · Reply

JarvisFlow Oct. 20 at 3:25 PM

Morgan Stanley has adjusted their stance on BeOne Medicines ( $ONC ), setting the rating to Overweight with a target price of 350 → 383.

0 · Reply

Estimize Oct. 20 at 11:06 AM

Wall St is expecting 0.83 EPS for $ONC Q3 [Reporting 11/13 BMO] http://www.estimize.com/intro/onc?chart=historical&metric_name=eps&utm_cont

0 · Reply

MoneyGroupLLC Oct. 20 at 5:44 AM

Enter: $ONC NOV 21 2025 $320 CALLS Buy in Price: $19.40 - $20.50 Take Profit: $45.59 Stop Bleeding: $17.07 ROI Potential: 135% Exit Within: 3 Weeks https://moneygroup.us/alerts

0 · Reply

MoneyGroupLLC Oct. 19 at 4:41 AM

Enter: $ONC NOV 21 2025 $320 CALLS Buy in Price: $19.40 - $20.50 Take Profit: $33.95 Stop Bleeding: $17.07 ROI Potential: 75% Exit Within: 3 Weeks https://moneygroup.us/alerts

0 · Reply

MoneyGroupLLC Oct. 18 at 9:07 AM

Enter: $ONC NOV 21 2025 $320 CALLS Buy in Price: $19.40 - $20.50 Take Profit: $41.71 Stop Bleeding: $17.07 ROI Potential: 115% Exit Within: 3 Weeks https://moneygroup.us/alerts

0 · Reply

MoneyGroupLLC Oct. 16 at 4:55 PM

Enter: $ONC NOV 21 2025 $320 CALLS Buy in Price: $21.50 - $22.30 Take Profit: $34.83 Stop Bleeding: $18.92 ROI Potential: 62% Exit Within: 3 Weeks https://moneygroup.us/alerts

0 · Reply

MaverikIT Oct. 16 at 1:49 PM

@IsabellaDC @TheLongVol $KORU $PKX $SE $ONC $SIMO

1 · Reply

MoneyGroupLLC Oct. 15 at 10:50 AM

Enter: $ONC NOV 21 2025 $330 CALLS Buy in Price: $14.70 - $21.20 Take Profit: $20.14 Stop Bleeding: $12.94 ROI Potential: 37% Exit Within: 1 Weeks https://moneygroup.us/alerts

0 · Reply

BeOne Medicines to Announce Third Quarter 2025 Financial Results on November 6

Oct 20, 2025, 6:00 AM EDT - 5 days ago

BeOne Medicines Presents New Data on TEVIMBRA in Lung Cancer at ESMO 2025

Oct 14, 2025, 4:24 PM EDT - 10 days ago

BeOne Medicines: Sonrotoclax Could Set Next Stage Of Growth For Hematology Pipeline

Oct 13, 2025, 6:00 AM EDT - 12 days ago

BeOne Medicines' Sonrotoclax Granted Breakthrough Therapy Designation by U.S. FDA

Sep 8, 2025, 5:26 PM EDT - 6 weeks ago

BeOne Medicines AG (ONC) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference (Transcript)

Aug 29, 2025, 10:16 AM EDT - 2 months ago

BeOne Medicines Stock Gains Momentum With Early-Stage Trial Success For Pretreated Lymphoma Patients

$BeOne Medicines Announces Positive Topline Results for Sonrotoclax in Relapsed or Refractory Mantle Cell Lymphoma (MCL)$

Aug 29, 2025, 6:00 AM EDT - 2 months ago

BeOne Medicines Announces Positive Topline Results for Sonrotoclax in Relapsed or Refractory Mantle Cell Lymphoma (MCL)

Aug 27, 2025, 6:00 AM EDT - 2 months ago

European Commission Approves TEVIMBRA® as Neoadjuvant/Adjuvant NSCLC Treatment Ahead of Late-Breaking Data Presentation at WCLC 2025

Aug 26, 2025, 8:15 AM EDT - 2 months ago

BeOne Medicines: Brukinsa's Leadership And Royalty Sale Signal A Stronger Future

Aug 26, 2025, 6:01 AM EDT - 2 months ago

BeOne to Present at the Morgan Stanley 23rd Annual Global Healthcare Conference

Aug 25, 2025, 6:00 AM EDT - 2 months ago

BeOne Medicines Announces IMDELLTRA Royalty Purchase Agreement for up to $950 Million

RPRX

Aug 21, 2025, 6:00 AM EDT - 2 months ago

European Commission Approves Tablet Formulation of BeOne Medicines' BRUKINSA® for All Approved Indications

Aug 6, 2025, 1:36 PM EDT - 2 months ago

BeOne Medicines Ltd. (ONC) Q2 2025 Earnings Call Transcript

Aug 6, 2025, 6:00 AM EDT - 2 months ago

BeOne Medicines Announces Second Quarter 2025 Financial Results and Business Updates

Aug 1, 2025, 8:31 AM EDT - 3 months ago

Pres. Trump's push to lower drug prices 'is a good starting point', says Dr. Scott Gottlieb

ABBV ABT ALNY AMGN ARGX AZN BAX

Aug 1, 2025, 6:54 AM EDT - 3 months ago

President Trump demands drugmakers slash prices within 60 days

ABBV ABT ALNY AMGN ARGX AZN BAX

Jul 31, 2025, 6:00 AM EDT - 3 months ago

BeOne Medicines Receives PRIME Designation from the European Medicines Agency for BGB-16673 in Waldenstrom's Macroglobulinemia

Jul 28, 2025, 6:00 AM EDT - 3 months ago

BeOne Medicines Receives Positive CHMP Opinion for TEVIMBRA® in Neoadjuvant/Adjuvant NSCLC Treatment

Jul 16, 2025, 6:00 AM EDT - 3 months ago

BeOne Medicines to Announce Second Quarter 2025 Financial Results on August 6

Jul 10, 2025, 6:00 AM EDT - 3 months ago

European Commission Approves TEVIMBRA® in Combination with Chemotherapy as a First-Line Treatment for Nasopharyngeal Carcinoma

Jul 9, 2025, 8:00 PM EDT - 3 months ago

Biocytogen Enters into Antibody Licensing Agreement with BeOne Medicines to Accelerate Innovative Drug Development

Jun 26, 2025, 6:00 AM EDT - 4 months ago

BeOne Medicines Showcases Groundbreaking Oncology Pipeline at R&D Day

Jun 25, 2025, 6:00 AM EDT - 4 months ago

BeOne Medicines Receives Positive CHMP Opinion for Tablet Formulation of BRUKINSA®

Jun 16, 2025, 11:06 AM EDT - 4 months ago

BeOne Medicines: Brukinsa Momentum And Pipeline Catalysts Justify Its Premium

Jun 12, 2025, 6:00 AM EDT - 4 months ago

BeOne Medicines Showcases Breakthrough Data in CLL and MCL at EHA 2025

Jun 11, 2025, 4:05 PM EDT - 4 months ago

U.S. FDA Approves Tablet Formulation of BeOne's BRUKINSA® for All Approved Indications

Jun 11, 2025, 6:01 AM EDT - 4 months ago

BeOne Medicines to Host Investor R&D Day Webcast on June 26, 2025

Jun 4, 2025, 7:08 AM EDT - 5 months ago

BeOne Medicines: Competitive Advantage Of Zanubrutinib In The CLL Field

Jun 2, 2025, 6:00 AM EDT - 5 months ago

BeOne Medicines Unveils Promising Clinical Data for Two Novel Breast Cancer Therapies at ASCO 2025

May 31, 2025, 8:00 AM EDT - 5 months ago

BeOne Medicines Presents New SEQUOIA Study Results Reinforcing BRUKINSA's Differentiated Profile with or without Venetoclax in Frontline CLL at ASCO 2025

May 27, 2025, 8:30 AM EDT - 5 months ago

BeOne Medicines Launches Following Redomiciliation to Switzerland, Marking a New Chapter in Global Oncology

May 27, 2025, 6:00 AM EDT - 5 months ago

BeiGene Receives Positive CHMP Opinion for TEVIMBRA® as a First-Line Treatment for Nasopharyngeal Cancer

May 22, 2025, 6:00 AM EDT - 5 months ago

BeiGene Presents Pioneering Cancer Research at ASCO 2025 – Redefining Treatment Across Hematology and Solid Tumors

May 14, 2025, 4:05 PM EDT - 5 months ago

BeiGene Showcases Strength of Hematology Portfolio at EHA 2025 with New Data Highlighting BRUKINSA's Leadership and Next-Generation Innovation

May 13, 2025, 6:01 AM EDT - 5 months ago

BeiGene to Present at the RBC Capital Markets Global Healthcare Conference

May 12, 2025, 1:05 PM EDT - 5 months ago

Undercovered Dozen: Richtech Robotics, Intesa Sanpaolo, BeiGene, Analog Devices +

ADI RR

May 8, 2025, 9:24 AM EDT - 6 months ago

BeiGene, Ltd., Soon To Be BeOne Medicines: New Name And New Profit

May 7, 2025, 2:04 PM EDT - 6 months ago

BeiGene, Ltd. (ONC) Q1 2025 Earnings Call Transcript

May 7, 2025, 11:01 AM EDT - 6 months ago

Chinese Biotech BeiGene Stock Falls Despite Strong Brukinsa Sales And Earnings Beat

May 7, 2025, 6:00 AM EDT - 6 months ago

BeiGene Announces First Quarter 2025 Financial Results and Business Updates

Apr 29, 2025, 3:32 PM EDT - 6 months ago

U.S. Patent and Trademark Office Invalidates Pharmacyclics Patent Asserted Against BeiGene

Apr 17, 2025, 6:01 AM EDT - 6 months ago

BeiGene to Announce First Quarter 2025 Financial Results on May 7

Apr 3, 2025, 11:19 AM EDT - 7 months ago

BeiGene Discontinues Lung Cancer Drug Study After Interim Data Showed Limited Survival Benefit

Apr 3, 2025, 6:00 AM EDT - 7 months ago

BeiGene Provides Update on the Ociperlimab (BGB-A1217) Clinical Development Program

Mar 31, 2025, 6:00 AM EDT - 7 months ago

BeiGene Receives Positive CHMP Opinion for TEVIMBRA® as a First-Line Treatment for Extensive-Stage Small Cell Lung Cancer

Mar 4, 2025, 8:37 AM EST - 8 months ago

China-Based Biotech BeiGene Scores FDA Approval For Tevimbra/Chemo Combo For Untreated Patients With Esophageal Cancer

Mar 4, 2025, 6:00 AM EST - 8 months ago

TEVIMBRA Approved in U.S. for First-line Treatment of Advanced Esophageal Squamous Cell Carcinoma in Combination with Chemotherapy

Feb 28, 2025, 2:00 PM EST - 8 months ago

BeiGene: Q4 Results Impress With Positive Earnings Expected In 2025

Feb 27, 2025, 10:24 AM EST - 8 months ago

BeiGene, Ltd. (ONC) Q4 2024 Earnings Call Transcript

Feb 27, 2025, 6:00 AM EST - 8 months ago

BeiGene Announces Fourth Quarter and Full Year 2024 Financial Results and Business Updates

SuperGreenToday Oct. 22 at 10:47 PM

0 · Reply

MoneyGroupLLC Oct. 22 at 7:25 AM

Enter: $ONC NOV 21 2025 $320 CALLS Buy in Price: $19.40 - $20.40 Take Profit: $44.81 Stop Bleeding: $17.07 ROI Potential: 131% Exit Within: 2 Weeks https://moneygroup.us/alerts

0 · Reply

JarvisFlow Oct. 20 at 3:25 PM

Morgan Stanley has adjusted their stance on BeOne Medicines ( $ONC ), setting the rating to Overweight with a target price of 350 → 383.

0 · Reply

Estimize Oct. 20 at 11:06 AM

Wall St is expecting 0.83 EPS for $ONC Q3 [Reporting 11/13 BMO] http://www.estimize.com/intro/onc?chart=historical&metric_name=eps&utm_cont

0 · Reply

MoneyGroupLLC Oct. 20 at 5:44 AM

Enter: $ONC NOV 21 2025 $320 CALLS Buy in Price: $19.40 - $20.50 Take Profit: $45.59 Stop Bleeding: $17.07 ROI Potential: 135% Exit Within: 3 Weeks https://moneygroup.us/alerts

0 · Reply

MoneyGroupLLC Oct. 19 at 4:41 AM

Enter: $ONC NOV 21 2025 $320 CALLS Buy in Price: $19.40 - $20.50 Take Profit: $33.95 Stop Bleeding: $17.07 ROI Potential: 75% Exit Within: 3 Weeks https://moneygroup.us/alerts

0 · Reply

MoneyGroupLLC Oct. 18 at 9:07 AM

Enter: $ONC NOV 21 2025 $320 CALLS Buy in Price: $19.40 - $20.50 Take Profit: $41.71 Stop Bleeding: $17.07 ROI Potential: 115% Exit Within: 3 Weeks https://moneygroup.us/alerts

0 · Reply

MoneyGroupLLC Oct. 16 at 4:55 PM

Enter: $ONC NOV 21 2025 $320 CALLS Buy in Price: $21.50 - $22.30 Take Profit: $34.83 Stop Bleeding: $18.92 ROI Potential: 62% Exit Within: 3 Weeks https://moneygroup.us/alerts

0 · Reply

MaverikIT Oct. 16 at 1:49 PM

@IsabellaDC @TheLongVol $KORU $PKX $SE $ONC $SIMO

1 · Reply

MoneyGroupLLC Oct. 15 at 10:50 AM

Enter: $ONC NOV 21 2025 $330 CALLS Buy in Price: $14.70 - $21.20 Take Profit: $20.14 Stop Bleeding: $12.94 ROI Potential: 37% Exit Within: 1 Weeks https://moneygroup.us/alerts

0 · Reply

Night_Owl_Biotech Oct. 14 at 1:54 PM

Change in share price of all commercial-stage oncology focused bios with market caps north of $300MM since last weeks close (using share prices this morning as of 9:40 AM). The XBI is off 2% where most in this peer group are off much more. $ZYME is clearly the biggest winner the last 5 trading days $ONC $GERN $NVCR SNDX & $AUTL are off the most in the peer group For information purposes only. This is not investment advice.

0 · Reply

MoneyGroupLLC Oct. 14 at 10:57 AM

Enter: $ONC NOV 21 2025 $330 CALLS Buy in Price: $24.50 - $34.35 Take Profit: $54.62 Stop Bleeding: $30.23 ROI Potential: 59% Exit Within: 2 Weeks https://moneygroup.us/alerts

0 · Reply

MoneyGroupLLC Oct. 12 at 9:18 AM

Enter: $ONC NOV 21 2025 $320 CALLS Buy in Price: $23.60 - $26.60 Take Profit: $54.75 Stop Bleeding: $20.77 ROI Potential: 132% Exit Within: 274 Minutes https://moneygroup.us/alerts

0 · Reply

MoneyGroupLLC Oct. 11 at 8:22 AM

Enter: $ONC NOV 21 2025 $320 CALLS Buy in Price: $23.60 - $26.60 Take Profit: $54.75 Stop Bleeding: $20.77 ROI Potential: 132% Exit Within: 274 Minutes https://moneygroup.us/alerts

0 · Reply

MoneyGroupLLC Oct. 10 at 5:20 AM

Enter: $ONC NOV 21 2025 $340 CALLS Buy in Price: $26.00 - $29.23 Take Profit: $49.40 Stop Bleeding: $25.72 ROI Potential: 69% Exit Within: 334 Minutes https://moneygroup.us/alerts

0 · Reply

MoneyGroupLLC Oct. 9 at 9:38 AM

Enter: $ONC NOV 21 2025 $360 CALLS Buy in Price: $23.00 - $24.30 Take Profit: $45.77 Stop Bleeding: $20.24 ROI Potential: 99% Exit Within: 266 Minutes https://moneygroup.us/alerts

0 · Reply

dodger100 Oct. 8 at 5:47 PM

$ONC JP Morgan raises PT to $385, maintains Overweight rating.

0 · Reply

BixbyKnolls Oct. 8 at 2:56 PM

$IBRX - So $MRK has a 10 percent position in $ONC . This BeOne Medicine doing trials on checkpoints with IBRX' Anktiva combo. Some results soon?

0 · Reply

dodger100 Oct. 8 at 12:22 PM

$ONC RBC increases PT to $374. Keeps Outperform rating

0 · Reply

MoneyGroupLLC Oct. 8 at 7:18 AM

Enter: $ONC NOV 21 2025 $350 CALLS Buy in Price: $23.00 - $24.60 Take Profit: $49.22 Stop Bleeding: $20.24 ROI Potential: 114% Exit Within: 231 Minutes https://moneygroup.us/alerts

0 · Reply

MoneyGroupLLC Oct. 7 at 3:48 AM

Enter: $ONC NOV 21 2025 $350 CALLS Buy in Price: $21.00 - $24.40 Take Profit: $51.03 Stop Bleeding: $18.48 ROI Potential: 143% Exit Within: 292 Minutes https://moneygroup.us/alerts

0 · Reply

MoneyGroupLLC Oct. 5 at 1:48 PM

Enter: $ONC NOV 21 2025 $350 CALLS Buy in Price: $21.00 - $26.40 Take Profit: $41.37 Stop Bleeding: $18.48 ROI Potential: 97% Exit Within: 122 Minutes https://moneygroup.us/alerts

0 · Reply

Market Cap	23.65B
Revenue (ttm)	3.81B
Net Income (ttm)	-644.79M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	318.72
Profit Margin	-16.92%
Debt to Equity Ratio	0.05

Volume	189,200
Avg Vol	468,388
Day's Range	N/A - N/A
Shares Out	99.25M
Stochastic %K	82%
Beta	0.35
Analysts	Strong Sell
Price Target	$321.39